Overview
- Eli Lilly will build a $5 billion plant in Goochland County, Virginia, launching the first of four new U.S. facilities in a capital program totaling more than $50 billion since 2020.
- The site will be Lilly’s first fully integrated active ingredient and drug product facility for its bioconjugate platform, focused on antibody‑drug conjugates and monoclonal antibodies.
- Lilly plans to begin making medicines at all four new sites within five years; the Virginia project is expected to generate about 650 permanent jobs plus 1,800 construction roles.
- The company selected Goochland from several hundred proposals, and the project is eligible for up to $130 million in Virginia MEI incentives pending General Assembly approval.
- CEO Dave Ricks said some production will shift from European sites and third‑party manufacturers to the Virginia facility as the company reinforces its U.S. supply chain under tariff pressure.